Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab biomarker study in synovial tissue for rheumatoid arthritis
NL-OMON30623Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adalimumab in rheumatoid arthritis (RA), sponsored by Amsterdam University Medical Center. Primary endpoint: Change in synovial cellular infiltrate and cytokine expression. Planned start Jan 2007; status: not yet recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON30623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30623.